HEAD-TO-HEAD COMPARISON
Wegovy vs ZepboundSemaglutide vs Tirzepatide
Verdict: Zepbound (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Wegovy (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Wegovy has a longer real-world track record and broader insurance coverage in some plans.
Side-by-side comparison
| Wegovy | Zepbound | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approval | 2021 | 2023 |
| Indication | Chronic weight management for adults with BMI 30+, or 27+ with at least one weight-related comorbidity | Chronic weight management for adults with BMI 30+, or 27+ with at least one weight-related comorbidity |
| Starting dose | Step 1 of 5 | Step 1 of 6 |
| Maintenance target | 2.4 mg/week | 15 mg/week |
| Titration length | ~17 weeks | ~21 weeks |
| Mean weight loss | ~14.9% mean at 68 weeks (STEP-1) | ~20.9% mean at 72 weeks (SURMOUNT-1) |
| HbA1c reduction | ~1.6 pp (off-label in T2D) | ~2.2 pp (off-label in T2D) |
| Cost (US list) | ~$1,350 / mo US list | ~$1,060 / mo US list |
| Insurance | Patchy for obesity indication | Patchy for obesity indication |
Who should pick which
- Pick Wegovy if the primary goal is weight management with an obesity-indicated label. Higher maintenance dose and stronger trial weight-loss data.
- Consider Zepbound (tirzepatide) if mean weight loss in published trials is the deciding factor. Dual GIP + GLP-1 mechanism produces the largest effect size in head-to-head data.
- Consider Wegovy for chronic weight management use cases; titration completes in roughly 17 weeks.
- Consider Zepbound for chronic weight management use cases; titration completes in roughly 21 weeks.
Switching between the two
Transitioning between semaglutide and tirzepatide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Open Semaglutide Dose Calculator → Compare full titration schedules side by sideFrequently asked
Is Wegovy better than Zepbound?
Zepbound (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Wegovy (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Wegovy has a longer real-world track record and broader insurance coverage in some plans.
Can I switch from Wegovy to Zepbound?
Transitioning between semaglutide and tirzepatide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Does Wegovy produce more weight loss than Zepbound?
Wegovy: ~14.9% mean at 68 weeks (STEP-1). Zepbound: ~20.9% mean at 72 weeks (SURMOUNT-1). Direct comparisons depend on dose, duration, and population studied; check the linked trial citations on each brand page for full context.
Why is Wegovy priced differently from Zepbound?
Wegovy costs ~$1,350 / mo US list; Zepbound costs ~$1,060 / mo US list. Differences reflect manufacturer pricing strategy, FDA indication (obesity-labeled brands often face patchier insurance coverage than diabetes-labeled brands), and whether the product is a finished drug or a pharmacy compound.
Which is better for Type 2 diabetes, Wegovy or Zepbound?
Both Wegovy and Zepbound address T2D-relevant pathways via GLP-1 receptor activity. Trial HbA1c reductions: Wegovy ~1.6 pp (off-label in T2D); Zepbound ~2.2 pp (off-label in T2D).
Related
For research informational use only. Not medical advice. Wegovy is a registered trademark of its manufacturer. Consult a qualified healthcare provider for clinical decisions.